TRX 818

Drug Profile

TRX 818

Alternative Names: CVM-1118; TRX-818

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator TaiRx
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Taiwan (PO) (NCT02703298)
  • 29 Jul 2015 TaiRx plans phase I trials in Cancer in USA (NCT02507544)
  • 15 Jul 2015 TaiRx files IND applications for phase I trials of TRX 818 in Cancer in Taiwan and USA before July 2015 (TaiRx website, July 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top